ArticleJournal of thrombosis and thrombolysis2026
Verification and optimization of the VTE risk stratification system for multiple myeloma.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a common complication in multiple myeloma (MM), particularly within the first six months of treatment initiation and disease relapse. This study optimized the MM-VTE risk stratification system to enable early and accurate identification of VTE risk. We retrospectively analyzed 433 newly diagnosed MM (NDMM) patients from Fu Xing Hospital, Capital Medical University, who were divided into derivation (n = 332) and validation (n = 101) cohorts. Independent risk factors were identified using univariate and multivariate analyses. The optimized MM-VTE risk stratification system was constructed by integrating the identified independent risk factors and thromboprophylaxis status. Model performance was assessed using the area under the curve (AUC). Internal validation was performed with bootstrap resampling, and external validation was conducted using the validation cohort. In the derivation cohort, the 6-month VTE incidence was 8.43% (28/332). Independent risk factors included female sex, bed rest at diagnosis, and platelet count above the upper limit of normal. The optimized MM-VTE risk stratification system was developed by integrating these factors and thromboprophylaxis. The AUC for the IMWG score was 0.605, and the AUCs for the MM-VTE risk stratification system before and after optimization were 0.660 and 0.742, respectively. In the validation cohort, the AUCs of the MM-VTE risk stratification system before and after optimization were 0.659 and 0.730, respectively.The optimized MM-VTE risk stratification system demonstrated improved discriminatory performance in our cohort, offering a potentially more reliable and clinically accessible tool for guiding thromboprophylaxis in Chinese patients.
Indexed as
Identifiers
42268504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.